Narciclasine - A Potential Anticancer Drug

2013 ◽  
Vol 411-414 ◽  
pp. 3154-3157 ◽  
Author(s):  
Yu Bin Ji ◽  
Chun Hui Song ◽  
Ning Chen ◽  
Dong Xue Song ◽  
Yan Dong ◽  
...  

Narciclasine (NCS) is a plant growth inhibitor isolated from the secreted mucilage of Narcissus tazetta bulbs, which is commonly used anticancer agent in human systems. Refer to the literatures in recent years, this article reviewed the anti-cancer effects of potential anticancer drugsNarciclasine, which induces apoptosis by activation of the death receptor and/or mitochondrial pathways in cancer cells. Narciclasine displays antitumor effects in apoptosis-resistant as well as in apoptosis-sensitive cancer cells by impairing the organization of the actin cytoskeleton.

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Takashi Ishida ◽  
Haruna Yoshimura ◽  
Masatsugu Takekawa ◽  
Takumi Higaki ◽  
Takashi Ideue ◽  
...  

AbstractThe discovery and useful application of natural products can help improve human life. Chemicals that inhibit plant growth are broadly utilized as herbicides to control weeds. As various types of herbicides are required, the identification of compounds with novel modes of action is desirable. In the present study, we discovered a novelN-alkoxypyrrole compound, kumamonamide fromStreptomyces werraensisMK493-CF1 and established a total synthesis procedure. Resulted in the bioactivity assays, we found that kumamonamic acid, a synthetic intermediate of kumamonamide, is a potential plant growth inhibitor. Further, we developed various derivatives of kumamonamic acid, including a kumamonamic acid nonyloxy derivative (KAND), which displayed high herbicidal activity without adverse effects on HeLa cell growth. We also detected that kumamonamic acid derivatives disturb plant microtubules; and additionally, that KAND affected actin filaments and induced cell death. These multifaceted effects differ from those of known microtubule inhibitors, suggesting a novel mode of action of kumamonamic acid, which represents an important lead for the development of new herbicides.


1972 ◽  
Vol 180 (1060) ◽  
pp. 317-346 ◽  

The naturally occurring plant growth inhibitor xanthoxin which was discovered in these laboratories has been prepared in vitro by the oxidation of the pigment violaxanthin with neutral zinc permanganate solution. By the use of chemical and spectroscopic techniques, xanthoxin has been characterized as a mixture of the 2- cis , 4- trans - and 2- trans , 4- trans -isomers of 5-(1', 2', -epoxy-4'-hydroxy-2', 6', 6'-tri-methyl-1'-cyclohexy)-3-methyl-pentadienal. These are also obtained by similar oxidations of neoxanthin, antheraxanthin and lutein epoxide. Cis, trans -xanthoxin probably arises from the corresponding cis -xanthophyll and its conversion to ( + )-ABA by simple chemical procedures is reported. The biological activity of cis, trans -xanthoxin has been shown to be considerably greater than that of the trans, trans -isomer. It is comparable with that of ( ± )-ABA in the wheat coleoptile section, the lettuce hypocotyl and bean petiole abscission tests, but greater than that of ( ± )-ABA in the cress seed germination test. Xanthoxin is shown to antagonize the growth-promoting effects of the plant hormones 3-indolylacetic acid, gibberellic acid and kinetin. Other xanthoxin derivatives have been prepared and their activities in several tests are also reported. The uptake of xanthoxin by tomato shoots leads to a subsequent large increase in the ABA content of the tissue. Evidence is presented for a possible biogenetic conversion of cis, trans -xanthoxin into ( + )-ABA by plants.


Author(s):  
Matharage Gayani Dilshara ◽  
Ilandarage Menu Neelaka Molagoda ◽  
Rajapaksha Gedara Prasad Tharanga Jayasooriya ◽  
Yung Hyun Choi ◽  
Cheol Park ◽  
...  

Indirubin-3′-monoxime (I3M) exhibits anti-proliferative activity in various cancer cells; however, its anti-cancer mechanism remains incompletely elucidated. This study revealed that I3M promotes the expression of death receptor 5 (DR5) and tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) in HCT116 p53+/+ cells, resulting in caspase-mediated apoptosis. However, this study demonstrated that HCT116 p53-/- cells are insensitive to I3M-mediated apoptosis, indicating that I3M-induced apoptosis depends on the p53 status of HCT116 cells. Additionally, in HCT116 p53-/- cells, I3M significantly increased Ras expression, while in HCT116 p53+/+ cells, it reduced Ras expression. Furthermore, I3M remarkably increased the production of reactive oxygen species (ROS), which were reduced in transient p53 knockdown, indicating that I3M-mediated apoptosis is promoted by p53-mediated ROS production. Our results also showed that I3M enhanced transcription factor C/EBP homologous protein (CHOP) expression, resulting in endoplasmic reticulum (ER) stress-mediated DR5 expression, which is upregulated by ROS production in HCT116 p53+/+ cells. Moreover, co-treatment with TRAIL synergistically enhanced I3M-induced DR5 expression, thereby triggering TRAIL-induced apoptosis of HCT116 p53+/+ cells, which was interfered by a DR5-specific blocking chimeric antibody. In summary, I3M potently enhances TRAIL-induced apoptosis by upregulating DR5 expression via p53-mediated ROS production in HCT116 p53+/+ cells. However, HCT116 p53-/- cells were resistant to I3M-mediated apoptosis, suggesting that I3M could be a promising anti-cancer candidate against TRAIL-resistant p53+/+ cancer cells.


2021 ◽  
Vol 11 ◽  
Author(s):  
Zongliang Lu ◽  
Wei Song ◽  
Yaowen Zhang ◽  
Changpeng Wu ◽  
Mingxing Zhu ◽  
...  

Castration-resistant (androgen-independent) and PTEN-deficient prostate cancer is a challenge in clinical practice. Sorafenib has been recommended for the treatment of this type of cancer, but is associated with several adverse effects. Platycodin D (PD) is a triterpene saponin with demonstrated anti-cancer effects and a good safety profile. Previous studies have indicated that PC3 cells (PTEN -/-, AR -/-) are sensitive to PD, suggesting that it may also be a useful treatment for castration-resistance prostate cancer. We herein investigated the effects of combining PD with sorafenib to treat PTEN-deficient prostate cancer cells. Our data show that PD promotes sorafenib-induced apoptosis and cell cycle arrest in PC3 cells. Of interest, PD only promoted the anti-cancer effects of sorafenib in Akt-positive and PTEN-negative prostate cancer cells. Mechanistic studies revealed that PD promoted p-Akt ubiquitination by increasing the p-Akt level. PD also increased the protein and mRNA expression of FOXO3a, the downstream target of Akt. Meanwhile, PD promoted the activity of FOXO3a and increased the protein expression of Fasl, Bim and TRAIL. Interestingly, when FOXO3a expression was inhibited, the antitumor effects of both PD and sorafenib were individually inhibited, and the more potent effects of the combination treatment were inhibited. Thus, the combination of PD and sorafenib may exert potent anti-cancer effects specifically via FOXO3a. The use of Akt inhibitors or FOXO3a agonists, such as PD, may represent a promising approach for the treatment of androgen-independent and PTEN-deficient prostate cancer.


2019 ◽  
Vol 14 (5) ◽  
pp. 1934578X1984578
Author(s):  
Sirinapa Chaipon ◽  
Sutjaritpan Boonmee ◽  
Arihiro Iwasaki ◽  
Kiyotake Suenaga ◽  
Hisashi Kato-Noguchi

A plant growth inhibitory substance was isolated from Heliotropium indicum by bioassay-guided purification and characterized to be (+)-isoamericanol A. (+)-Isoamericanol A significantly inhibited seedling growth of cress at a concentration greater than 0.1 mM. The concentrations of (+)-isoamericanol A required for 50% growth inhibition of cress roots and hypocotyls were 0.5 and 0.4 mM, respectively. This inhibition indicates that (+)-isoamericanol A had a growth inhibitory activity and may contribute to the allelopathic effect of H. indicum. This report is the first on the plant growth inhibitory activity of (+)-isoamericanol A as an allelopathic substance.


1977 ◽  
Vol 41 (8) ◽  
pp. 1539-1541 ◽  
Author(s):  
Michimasa Ikeda ◽  
Yoshifumi Sato ◽  
Masaharu Izawa ◽  
Takeshi Sassa ◽  
Yukichi Miura

2005 ◽  
Vol 46 (2) ◽  
pp. 125-131 ◽  
Author(s):  
Sayaka Morita ◽  
Syuntaro Hiradate ◽  
Yoshiharu Fujii ◽  
Jiro Harada

Sign in / Sign up

Export Citation Format

Share Document